<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02598505</url>
  </required_header>
  <id_info>
    <org_study_id>R111/14 CCM 89</org_study_id>
    <nct_id>NCT02598505</nct_id>
  </id_info>
  <brief_title>Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation</brief_title>
  <official_title>Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Cardiologico Monzino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Cardiologico Monzino</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are:

        1. To confirm safety of Indacaterol in stable Heart Failure.

        2. To determine whether beta 2 alveolar receptor stimulation by Indacaterol is able to
           ameliorate lung diffusion in heart Failure patients treated with beta blockers.

        3. To compare the effects of Indacaterol in patients treated with a non-selective beta
           blocker (Carvedilol) and a beta 1-selective beta blocker (Bisoprolol).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measurement of change in lung diffusion of carbon monoxide (CO).</measure>
    <time_frame>day 0, 60, 74, 134</time_frame>
    <description>comparison of change in lung diffusion of carbon monoxide after treatment placebo/indacaterol between the carvedilol and bisoprolol groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>measurement of change in Dm</measure>
    <time_frame>day 0, 60, 74, 134</time_frame>
    <description>comparison of change in Dm after treatment placebo/indacaterol between the carvedilol and bisoprolol groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>measurement of change in Vc</measure>
    <time_frame>day 0, 60, 74, 134</time_frame>
    <description>comparison of change in Vc after treatment placebo/indacaterol between the carvedilol and bisoprolol groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>measurement of change in lung diffusion of NO (Nitric Oxide)</measure>
    <time_frame>day 0, 60, 74, 134</time_frame>
    <description>Measurement of change in lung diffusion of nitric oxide after treatment placebo/indacaterol between the carvedilol and bisoprolol groups.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Indacaterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inside this arm we also compare the effect of Carvedilol to the effect of Bisoprolol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inside this arm we also compare the effect of Carvedilol to the effect of Bisoprolol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacaterol</intervention_name>
    <arm_group_label>Indacaterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female adults aged â‰¥ 18 years who have signed an Informed Consent Form.

          -  Patients with light chronic obstructive pulmonary disease never treated with
             bronchodilator drugs

          -  Co-operative patients

          -  Patients with a clinical diagnosis of chronic heart failure (HF)

          -  chronic myeloproliferative disorder with ejection fraction &lt; 40% with B Blockers
             therapy since at least 2 months. Optimized and individually tailored drug treatment
             including B blocker (Carvedilol or bisoprolol)

          -  Capability of performing Cardiopulmonary Exercise Test and lung diffusion test

        Exclusion Criteria:

        History or clinical documentation of:

          -  pulmonary embolism

          -  primary valvular heart disease

          -  pericardial disease

          -  severe obstructive lung disease

          -  significant peripheral vascular disease

          -  exercise-induced angina, st changes, or severe arrhythmias.

          -  Patients with diabetes Type I or uncontrolled diabetes Type II including patients with
             a history of blood glucose levels consistently outside the normal range or HbA1c &gt; 8.0
             % of total hemoglobin measured.

          -  Use of bronchodilators.

          -  Patients with a history (or family history) of long QT syndrome or whose corrected QT
             interval interval (Fridericia) measured at Visit 2 is prolonged: &gt;450 ms (males) or
             &gt;470 ms (females) as assessed by the central ECG interpretation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piergiuseppe Agostoni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Cardiologico Monzino</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Piergiuseppe Agostoni, MD PhD</last_name>
    <phone>0039 02 5800</phone>
    <phone_ext>2772</phone_ext>
    <email>piergiuseppe.agostoni@ccfm.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mauro Contini, MD</last_name>
    <phone>0039 02 5800</phone>
    <phone_ext>2525</phone_ext>
    <email>mauro.contini@ccfm.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piergiuseppe Agostoni, MD. PhD</last_name>
      <phone>0039 02 5800</phone>
      <phone_ext>2772</phone_ext>
    </contact>
    <investigator>
      <last_name>Piergiuseppe Agostoni, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2015</study_first_posted>
  <last_update_submitted>November 4, 2015</last_update_submitted>
  <last_update_submitted_qc>November 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Cardiologico Monzino</investigator_affiliation>
    <investigator_full_name>Piergiuseppe Agostoni</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

